All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma

October 10th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML

October 9th 2022

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management

October 8th 2022

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

Luspatercept Demonstrates Long-Term Anemia Benefit in Lower-Risk MDS

October 7th 2022

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma

October 7th 2022

Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.

Efforts Underway to Generate Real-World Evidence for Second-line Strategies in SCLC

October 7th 2022

Nicolas Girard, MD, PhD, highlights current treatment practices, the value real-world data would provide for future investigative approaches in SCLC, and the observed benefit of administering available treatment options such as lurbinectedin as early as possible.

Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer

October 7th 2022

The combination of pegylated liposomal doxorubicin, cyclophosphamide, trastuzumab, and pertuzumab elicited encouraging responses with acceptable safety when given as neoadjuvant treatment in patients with HER2-positive breast cancer.

Sylvester Grant Funds Early-Stage Prostate Cancer Study

October 7th 2022

Researchers are investigating ways to make immunotherapies more effective.

Phase 2 ENVASARC Trial of Envafolimab With and Without Ipilimumab in Sarcoma to Continue

October 7th 2022

An independent data monitoring committee has recommended that the phase 2 ENVASARC trial examining envafolimab with and without ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma continue as planned.

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera

October 7th 2022

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Trastuzumab Deruxtecan Expands Metastatic Breast Cancer Treatment Landscape Across HER2-Expressing Subtypes

October 7th 2022

Jane Lowe Meisel, MD, discussed the emergence of HER2-low as a new category in breast cancer, outlining the significance of the phase 3 DESTINY-Breast04 trial and the unique qualities of trastuzumab deruxtecan in the HER2-positive and HER2-low populations.

Neratinib Elicits Durable Responses in Metastatic or Recurrent HER2-Mutated Cervical Cancer

October 6th 2022

Single-agent neratinib produced robust responses in patients with metastatic or recurrent HER2-mutated cervical cancer, according to updated data from phase 2 SUMMIT basket trial.

Sonpavde Reviews Urothelial Carcinoma Treatment Highlights from ESMO 2022

October 6th 2022

Guru P. Sonpavde, MD, provides commentary on several studies in urothelial carcinoma and how data presented at ESMO may affect clinical practice.

DZD1516 Demonstrates Safety, Early Activity in Heavily Pretreated Metastatic HER2+ Breast Cancer

October 6th 2022

DZD1516 monotherapy elicited early clinical activity and was found to be well tolerated in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC

October 6th 2022

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

Ivosidenib/Venetoclax/Azacitidine Proves Tolerable, Strengthens Survival in AML

October 6th 2022

Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.

The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities

October 6th 2022

The American Cancer Society has awarded Montefiore Einstein Cancer Center more than $2.1 million to support cancer research and reduce individual and systematic barriers that prevent people from accessing cancer care.

Investigators Lay Groundwork for Exploring TROP-2 as a Therapeutic Target in NSCLC

October 6th 2022

Clinicians looking for additional options for the treatment of patients with non–small cell lung cancer may soon be gaining another actionable biomarker with the emergence of exciting new data concerning targeting the cell-surface glycoprotein TROP-2.

Patient-Reported Outcomes Support Use of Trastuzumab Deruxtecan in HR+/HER2-Negative Breast Cancer

October 6th 2022

Fam-trastuzumab deruxtecan-nxki preserved quality of life vs physicians choice of treatment in patients with advanced, hormone receptor–positive/HER2-low metastatic breast cancer.

Pembrolizumab Improves Outcomes Regardless of Response to Prior Chemotherapy in Advanced Urothelial Cancer

October 5th 2022

Response to pembrolizumab monotherapy was observed regardless of prior response to chemotherapy in patients with advanced urothelial cancer.